Investtech.com

Analysis

Global stocks: 3 solid buys - Apple Inc, Thomson Reuters Corp and Johnson & Johnson

Published September 13, 2018

Share prices are a broader picture of investor sentiment and demand-supply, and a direct representation of what is happening inside a company or an instrument. Whether it is a bite of an APPLE, a news coverage by the service provider Thomson Reuters or the Fortune 500 listed Johnson & Johnson, everything is reflected in their share prices. With the use of technical analysis we analyze how seriously or not investors think about these companies - shown in the charts below.

Apple Inc (AAPL.US) Close: 221.07


Apple Inc broke out of the upper trendline of the rising trend channel in the medium term. This signals increasing optimism among investors and indicates continued rise. The rise in stock price is supported by high volume and any correction is supported by low volume. This indicates a positive volume balance. The stock is currently under its short term high of 228 and a break out from that level may initiate new buying. However, in case of a correction, there is support around 190.
Apple Inc came up with new announcements on Wednesday September 12, and it would be interesting to see how investors and traders will react to it in coming trading sessions.
This stock is listed on NASDAQ and is traded in USD.
Investtech's recommendation: Buy

 

Thomson Reuters Corp (TRI.US) Close: 45.22 (+0.65)


Thomson Reuters Corp shows strong development within a rising trend channel in the medium term. Rising trends indicate that the company experiences positive development and that buy interest among investors is increasing. The stock has broken up through the resistance at dollar 44.90. This predicts a further rise. There is support around 42.50 and resistance around 48.
RSI is above 70 after a good price increase the past weeks. The stock has strong positive momentum and positive volume balance. Further increase in stock price is indicated.
Thomas Reuters Inc is listed on NYSE and is traded in USD.
Investtech's recommendation: Buy

 

Johnson & Johnson (JNJ.US) Close: 139.36 (+0.85)


Pharmaceutical giant Johnson & Johnson is in a rising trend channel. This indicates that investors are positive about the company's future and have steadily paid higher prices to buy stock in the company. Further rise in price is suggested.
Currently the stock is trading around its earlier resistance of 136 and is inching towards its previous all-time-high of 148. A breakout above that level will initiate a new buy signal.
The stock now has support around 133-136 levels. Volume balance indicator is very positive, something that indicates that buyers outnumber sellers. Also, the momentum indicator RSI is over 70 that suggests strong underlying momentum in the stock. Together these indicators support the rising trend in Johnson and Johnson.
The stock is traded on NYSE and is traded in USD.
Investtech's recommendation: Buy

 

Our analysis is majorly based on trend, as it is said, ‘trend is your best friend’, with more focus on the medium term chart. We also take into account price formations and volume, and momentum indicators. More can be read about Investtech's research at www.thetrendbible.com.

Note: These stocks are traded in currency based on the country they are listed on.

 

 

The analyses are based on closing price as per September 12, 2018.

Written by

Kiran R. Shroff

Analyst - Investtech

"Investtech analyses the psychology of the market and gives concrete trading suggestions every day."

Espen Grønstad
Partner & Senior Advisor - Investtech
 


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.


Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer. The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.

Titlex

OK
Free Trial Now